Onkológia 2/2014

Abiraterone in treatment of metastatic castrate resistant prostate cancer

Androgen deprivation therapy is the standard of care for metastatic prostate cancer but is uniformly progress to castration resistant disease dispite castration levels of serum testosterone. However, castrate levels of androgens does not eliminate androgens from the prostate and residual androgens are capable of activating the androgen receptors and androgen receptors –mediated gen expresion. Abiraterone is a specific inhibitor of CYP17A1 that blocks extragonadal, testicular and tumor androgen biosynthesis. Abiraterone constitues new era in the hormonal treatment of men with metastatic castrate resistant prostate cancer. This article reviews briefly recent data from phase III trials in metastatic castrate resistant prostate cancer treated with abiraterone and also some aspects of management of patients with metastatic castrate resistant prostate cancer.

Keywords: abiraterone, metastatic castrate resistant prostate cancer, androgen receptors.